Thousand Oaks secures $45m to expand its CDMO, CMC service offerings

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/seb_ra)
(Image: Getty/seb_ra)

Related tags: Contract manufacturing, CDMO, Finance, Biopharmaceutical, Contract manufacturing organisation, CMC, Biologics

Thousand Oaks Biopharmaceuticals raised $45m in Series A financing, enabling the company to expand its CDMO and CMC services as well as its capabilities in global biologics development.

After closing the Series A financing round, the company will advance its plans to create a Phase II contract development and manufacturing organization (CDMO). It has already begun construction of its large scale cell culture media (LSCCM) current good manufacturing processes (cGMP) facilities in Haimen, Nantong, China.

Shun Luo, chairman of Thousand Oaks Biopharmaceuticals, told us the agreement was in an aim to, “build up an integrated CMC bio-manufacturing infrastructure to quickly capture the fast growing biopharmaceutical industry in innovative therapeutics and therapy development.”

In a statement, Luo said that enhancements to its chemistry, manufacturing, and controls (CMC) capabilities will include cell line development, process and bioanalytical development, and customized cell culture media development. Together, these capabilities will establish an integrated platform from DNA to clinical material supplies and regulatory filings.

“Our integrated CMC capacity include those capacities for dry powder cell culture media manufacturing, disposable technology and all its related products including disposable bags and devices,”​ Luo explained.

The financing was led by New Alliance Capital, and included ADDOR Capital, Tenyall & Sumin, Broadhi Capital, OjanRong, Ji Lin Ao Dong, and Bluebay capital. 

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more